What is Processa Pharmaceuticals 3-Year Share Buyback Ratio?
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Processa Pharmaceuticals's current 3-Year Share Buyback Ratio was -67.60%.
The historical rank and industry rank for Processa Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:
PCSA'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -192.8 Med: -42.35 Max: -11.2
Current: -67.6
During the past 13 years, Processa Pharmaceuticals's highest 3-Year Share Buyback Ratio was -11.20%. The lowest was -192.80%. And the median was -42.35%.
PCSA's 3-Year Share Buyback Ratio is ranked worse than 90.05% of 1286
companies
in the Biotechnology industry
Industry Median: -10.35
vs PCSA: -67.60
Competitive Comparison of Processa Pharmaceuticals's 3-Year Share Buyback Ratio
For the Biotechnology subindustry, Processa Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's 3-Year Share Buyback Ratio falls into.
Processa Pharmaceuticals 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
Processa Pharmaceuticals (NAS:PCSA) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Processa Pharmaceuticals 3-Year Share Buyback Ratio Related Terms
Thank you for viewing the detailed overview of Processa Pharmaceuticals's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCSA has been successfully added to your